Ascendis Pharma A/S - American Depositary Shares (ASND)
200.87
+6.60 (3.40%)
NASDAQ · Last Trade: Sep 2nd, 3:54 PM EDT
Detailed Quote
Previous Close | 194.27 |
---|---|
Open | 195.50 |
Bid | 200.55 |
Ask | 201.19 |
Day's Range | 194.21 - 203.59 |
52 Week Range | 111.09 - 199.99 |
Volume | 419,856 |
Market Cap | 11.48B |
PE Ratio (TTM) | - |
EPS (TTM) | - |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 548,112 |
Chart
About Ascendis Pharma A/S - American Depositary Shares (ASND)
Ascendis Pharma is a biotechnology company focused on developing innovative medicines using its proprietary TransCon technology platform. The company aims to address unmet medical needs, particularly in the areas of endocrine diseases and rare disorders, by creating optimally dosed therapies that enhance the bioavailability and efficacy of existing therapies. Through its robust pipeline, Ascendis Pharma is committed to advancing new treatment options that improve patient outcomes and quality of life, leveraging its expertise in drug development and deep understanding of biological mechanisms. Read More
News & Press Releases
Ascendis Pharma (ASND) excels in both technical & fundamental momentum, meeting Minervini's Trend Template criteria for high-growth stocks poised for potential outperformance.
Via Chartmill · September 1, 2025
Via Benzinga · August 19, 2025
Via Benzinga · August 6, 2025

Via Benzinga · May 29, 2025
Via Benzinga · August 4, 2025
Via Benzinga · July 28, 2025
Via Benzinga · July 22, 2025
Via Benzinga · July 7, 2025
Via Benzinga · June 12, 2025
Via Benzinga · May 21, 2025
Via Benzinga · May 6, 2025
Via Benzinga · May 5, 2025
A fundamental and technical analysis of (NASDAQ:ASND): Is ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) suited for high growth investing?
Via Chartmill · April 28, 2025
Via Benzinga · April 15, 2025
A fundamental and technical analysis of (NASDAQ:ASND): Why the high growth investor may take a look at ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND).
Via Chartmill · April 4, 2025
Via Benzinga · March 25, 2025
A fundamental and technical analysis of (NASDAQ:ASND): Why the high growth investor may take a look at ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND).
Via Chartmill · March 14, 2025